Changed adipocytokine concentrations in colorectal tumor patients and morbidly obese patients compared to healthy controls

BMC Cancer

Andreas Hillenbrand²  Juliane Fassler²  Nadine Huber²  Pengfei Xu²  Doris Henne-Bruns²  Markus Templin³  Hubert Schrezenmeier¹  Anna Maria Wolf²  Uwe Knippschild² 

[1] Institute of Clinical Tranfusion Medicine and Immunogenetics, Helmholtzstr. 10, 89081, Ulm, Germany

[2] Department of General and Visceral Surgery, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany

[3] NMI at the University of Tuebingen, Markwiesenstr. 55, 72770, Reutlingen, Germany

关键词: Resistin;    Leptin;    Adiponectin;    Morbid obesity;    Colorectal cancer;    Cytokine;    Adipocytokine;    Adipokine;   

Others  :  1080066
DOI  :  10.1186/1471-2407-12-545

 received in 2012-04-01, accepted in 2012-11-20,  发布年份 2012

【 摘 要 】

Background

Obesity has been associated with increased incidence of colorectal cancer. Adipose tissue dysfunction accompanied with alterations in the release of adipocytokines has been proposed to contribute to cancer pathogenesis and progression. The aim of this study was to analyze plasma concentrations of several adipose tissue expressed hormones in colorectal cancer patients (CRC) and morbidly obese (MO) patients and to compare these concentrations to clinicopathological parameters.

Methods

Plasma concentrations of adiponectin, resistin, leptin, active plasminogen activator inhibitor (PAI)-1, monocyte chemotactic protein (MCP)-1, interleukin (IL)-1 alpha, and tumor necrosis factor (TNF)-alpha were determined in 67 patients operated on for CRC (31 rectal cancers, 36 colon cancers), 37 patients operated on for morbid obesity and 60 healthy blood donors (BD).

Results

Compared to BD, leptin concentrations were lowered in CRC patients whereas those of MO patients were elevated. Adiponectin concentrations were only lowered in MO patients. Concentrations of MCP-1, PAI-1, and IL-1 alpha were elevated in both CRC and MO patients, while resistin and TNF-alpha were similarly expressed in MO and CRC patients compared to BD. Resistin concentrations positively correlated with tumor staging (p<0.002) and grading (p=0.015) of rectal tumor patients.

Conclusions

The results suggest that both MO and CRC have low-grade inflammation as part of their etiology.

【 授权许可】

   
2012 Hillenbrand et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]WHO: Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000, 894(i-xii):1-253.
• [2]Calle EE, Thun MJ: Obesity and cancer. Oncogene 2004, 23:6365-6378.
• [3]Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, Adam HO: A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001, 12:13-21.
• [4]Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4:579-591.
• [5]Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
• [6]Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M: Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
• [7]Siddiqui AA: Metabolic syndrome and its association with colorectal cancer: a review. Am J Med Sci 2010, 341:227-231.
• [8]Ford ES: Body mass index and colon cancer in a national sample of adult U.S. men and women. Am J Epidemiol 1999, 150:390-398.
• [9]MacInnis RJ, English DR, Hopper JL, Gertig DM, Haydon AM, Giles GG: Body size and composition and colon cancer risk in women. Int J Cancer 2006, 118:1496-1500.
• [10]Larsson SC, Wolk A: Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 2007, 86:556-565.
• [11]Siegel EM, Ulrich CM, Poole EM, Holmes RS, Jacobsen PB, Shibata D: The effects of obesity and obesity-related conditions on colorectal cancer prognosis. Cancer Control 2010, 17:52-57.
• [12]VanKruijsdijk RC, van der Wall E, Visseren FL: Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009, 18:2569-2578.
• [13]Phillips LK, Prins JB: The link between abdominal obesity and the metabolic syndrome. CurrHypertens Rep 2008, 10:156-164.
• [14]Dinarello CA: Proinflammatory cytokines. Chest 2000, 118:503-508.
• [15]Yamaji T, Iwasaki M, Sasazuki S, Tsugane S: Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res 2010, 70:5430-5437.
• [16]Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I, Palmirotta R, Ferroni P: Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res 2009, 29:3321-3327.
• [17]Osborn O, Gram H, Zorrilla EP, Conti B, Bartfai T: Insights into the roles of the inflammatory mediators IL-1, IL-18 and PGE2 in obesity and insulin resistance. Swiss Med Wkly 2008, 138:665-673.
• [18]Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L: The origin and function of tumor-associated macrophages. Immunol Today 1992, 13:265-270.
• [19]Sălăgeanu A, Tucureanu C, Lerescu L, Caraş I, Pitica R, Gangurà G, Costea R, Neagu S: Serum levels of adipokines resistin and leptin in patients with colon cancer. J Med Life 2010, 3:416-420.
• [20]Housa D, Housova J, Vernerova Z, Haluzik M: Adipocytokines and cancer. Physiol Res 2006, 55:233-244.
• [21]Lang K, Ratke J: Leptin and adiponectin: new players in the field of tumor cell and leukocyte migration. Cell Commun Signal 2009, 7:27. BioMed Central Full Text
• [22]Edge SE, Byrd DR, Carducci MA, Compton CC: AJCC cancer staging manual. 7th edition. New York, NY: Springer; 2010.
• [23]Sobin LH, Gospodarowicz MK, Wittekind C: UICC: TNM classification of malignant tumors. 7th edition. Oxford: Wiley-Blackwell; 2009.
• [24]Harvey AE, Lashinger LM, Hursting SD: The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci 2011, 1229:45-52.
• [25]Kelesidis I, Kelesidis T, Mantzoros CS: Adiponectin and cancer: a systematic review. Br J Cancer 2006, 94:1221-1225.
• [26]Stattin P, Lukanova A, Biessy C, Söderberg S, Palmqvist R, Kaaks R, Olsson T, Jellum E: Obesity and colon cancer: does leptin provide a link? Int J Cancer 2004, 109:149-152.
• [27]Kumor A, Daniel P, Pietruczuk M, Małecka-Panas E: Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis 2009, 24:275-281.
• [28]Stattin P, Palmqvist R, Söderberg S, Biessy C, Ardnor B, Hallmans G, Kaaks R, Olsson T: Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol Rep 2003, 10:2015-2021.
• [29]Aleksandrova K, Boeing H, Jenab M, Bueno-de-Mesquita HB, Jansen E, van Duijnhoven FJ, Fedirko V, Rinaldi S, Romieu I, Riboli E, Romaguera D, Westphal S, Overvad K, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Kaaks R, Lukanova A, Trichopoulou A, Lagiou P, Trichopoulos D, Agnoli C, Mattiello A, Saieva C, Vineis P, Tumino R, Peeters PH, Argüelles M, Bonet C, Sánchez MJ, Dorronsoro M, Huerta JM, Barricarte A, Palmqvist R, Hallmans G, Khaw KT, Wareham N, Allen NE, Crowe FL, Pischon T: Total and high-molecular weight adiponectin and risk of colorectal cancer: the European prospective investigation into cancer and nutrition study. Carcinogenesis 2012, 33:1-8.
• [30]Saxena A, Chumanevich A, Fletcher E, Larsen B, Lattwein K, Kaur K, Fayad R: Adiponectin deficiency: role in chronic inflammation induced colon cancer. BiochimBiophysActa 2012, 1822:527-536.
• [31]Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS: Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005, 97:1688-1694.
• [32]Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, Saito T, Togashi H, Nakamura T, Matsuzawa Y, Kawata S: Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res 2005, 11:3642-3646.
• [33]Ho GY, Wang T, Gunter MJ, Strickler HD, Cushman M, Kaplan RC, Wassertheil-Smoller S, Xue X, Rajpathak SN, Chlebowski RT, Vitolins MZ, Scherer PE, Rohan TE: Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res 2012, 72:3029-3037.
• [34]Chronis A, Thomopoulos K, Sapountzis A, Triantos C, Kalafateli M, Kalofonos C, Nikolopoulou V: Adiposity factors are not related to the presence of colorectal adenomas. ClinExpGastroenterol. 2011, 4:257-261.
• [35]Landskroner-Eiger S, Qian B, Muise ES, Nawrocki AR, Berger JP, Fine EJ, Koba W, Deng Y, Pollard JW, Scherer PE: Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res 2009, 15:3265-3276.
• [36]Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA: Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. BiochemBiophys Res Commun 2003, 300:472-476.
• [37]Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, Hamaguchi T, Shimada Y: Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010, 101:1286-1291.
• [38]Gonullu G, Kahraman H, Bedir A, Bektas A, Yücel I: Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis 2010, 25:205-212.
• [39]Cox GW, Melillo G, Chattopadhyay U, Mullet D, Fertel RH, Varesio L: Tumor necrosis factor-α–dependent production of reactive nitrogen intermediates mediates IFN-γ plus IL-2–induced murine macrophage tumoricidal activity. J Immunol 1992, 149:3290-3296.
• [40]Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J ClinEndocrinolMetab 1997, 82:4196-4200.
• [41]Sethi JK, Hotamisligil GS: The role of TNF alpha in adipocyte metabolism. Semin Cell DevBiol 1999, 10:19-29.
• [42]Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J PhysiolEndocrinolMetab 2001, 280:E745-E751.
• [43]Sternlicht MD, Dunning AM, Moore DH, Pharoah PD, Ginzinger DG, Chin K, Gray JW, Waldman FM, Ponder BA, Werb Z: Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors Are more important than genetic variation in regulating PAI1 expression cancer. Epidemiol Biomarkers Prev 2006, 15:2107-2114.
• [44]Nielsen HJ, Pappot H, Christensen IJ, Brünner N, Thorlacius-Ussing O, Moesgaard F, Danø K, Grøndahl-Hansen J: Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ 1998, 316:829-830.
• [45]Langenskiöld M, Holmdahl L, Angenete E, Falk P, Nordgren S, Ivarsson ML: Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. TumourBiol 2009, 30:210-220.
• [46]Angenete E, Langenskiöld M, Palmgren I, Falk P, Oresland T, Ivarsson ML: uPA and PAI-1 in rectal cancer–relationship to radiotherapy and clinical outcome. J Surg Res 2009, 153:46-53.
• [47]Deshmane SL, Kremlev S, Amini S, Sawaya BE: Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009, 29:313-326.
• [48]Siveen KS, Kuttan G: Role of macrophages in tumour progression. ImmunolLett 2009, 123:97-102.
• [49]Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S: Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol 2004, 99:1667-1674.
• [50]Bailey C, Negus R, Morris A, Ziprin P, Goldin R, Allavena P, Peck D, Darzi A: Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. ClinExp Metastasis 2007, 24:121-130.
• [51]Lewis AM, Varghese S, Xu H, Alexander HR: Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006, 4:48. BioMed Central Full Text
• [52]Matsuki T, Horai R, Sudo K, Iwakura Y: IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med 2003, 198:877-888.
• [53]Mertens I, Van Gaal LF: Visceral fat as a determinant of fibrinolysis and hemostasis. SeminVasc Med 2005, 5:48-55.
• [54]Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, Juhan-Vague I: Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. ArteriosclerThrombVascBiol 2003, 23:1262-1268.
• [55]Zhang J, Patel L, Pienta KJ: Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. ProgMolBiolTransl Sci. 2010, 95:31-53.